ATE302016T1 - Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind - Google Patents

Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind

Info

Publication number
ATE302016T1
ATE302016T1 AT95920641T AT95920641T ATE302016T1 AT E302016 T1 ATE302016 T1 AT E302016T1 AT 95920641 T AT95920641 T AT 95920641T AT 95920641 T AT95920641 T AT 95920641T AT E302016 T1 ATE302016 T1 AT E302016T1
Authority
AT
Austria
Prior art keywords
carriers
development
peptides used
constructs useful
synthetic vaccines
Prior art date
Application number
AT95920641T
Other languages
English (en)
Inventor
Irun R Cohen
Matityahu Fridkin
Stephanie Konen-Waisman
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE302016T1 publication Critical patent/ATE302016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95920641T 1994-05-25 1995-05-24 Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind ATE302016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10979094A IL109790A0 (en) 1994-05-25 1994-05-25 Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
PCT/US1995/006575 WO1995031994A1 (en) 1994-05-25 1995-05-24 Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines

Publications (1)

Publication Number Publication Date
ATE302016T1 true ATE302016T1 (de) 2005-09-15

Family

ID=11066168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920641T ATE302016T1 (de) 1994-05-25 1995-05-24 Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind

Country Status (8)

Country Link
EP (1) EP0760671B1 (de)
JP (1) JPH10504524A (de)
AT (1) ATE302016T1 (de)
AU (1) AU684369B2 (de)
CA (1) CA2191202A1 (de)
DE (1) DE69534382T2 (de)
IL (1) IL109790A0 (de)
WO (1) WO1995031994A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0700445T3 (da) 1993-06-04 2002-05-13 Whitehead Biomedical Inst Stressproteiner og anvendelser deraf
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
CA2282426A1 (en) * 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
ES2191929T3 (es) 1997-08-05 2003-09-16 Stressgen Biotechnologies Corp Respuestas inmunologicas contra los antigenos pvh estimuladas por composiciones que comprenden un antigeno pvh y una proteina de estres o un vector de expresion capaz de expresar dichas proteinas.
DE19821859A1 (de) * 1998-05-15 1999-12-09 M Alexander Schmidt Darstellung immunogener (Kapsel-)Polysaccharid-Konjugate durch orientierte Kupplung synthetischer T-Zell-Epitope zur Erzeugung von Vakzinen gegen N.meningitidis
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
EP1196772A2 (de) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induktion einer th1-vermittelten immunantwort in vitro
US6677139B1 (en) 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
DE60042704D1 (de) 2000-01-14 2009-09-17 Whitehead Biomedical Inst Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
BR0111956A (pt) 2000-06-26 2003-05-13 Stressgen Biotechnologies Corp Tratamento do vìrus do papiloma humano
IT1319277B1 (it) * 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
BR0206995A (pt) 2001-02-05 2005-08-16 Stressgen Biotechnologies Corp Tratamento do vìrus da hepatite b
AUPR852301A0 (en) * 2001-10-26 2001-11-29 Medvet Science Pty. Ltd. Groel chimeric protein and vaccine
WO2006097914A2 (en) * 2005-03-14 2006-09-21 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them

Also Published As

Publication number Publication date
JPH10504524A (ja) 1998-05-06
DE69534382D1 (de) 2005-09-22
IL109790A0 (en) 1994-08-26
AU684369B2 (en) 1997-12-11
AU2602795A (en) 1995-12-18
WO1995031994A1 (en) 1995-11-30
EP0760671A1 (de) 1997-03-12
EP0760671A4 (de) 1999-11-17
DE69534382T2 (de) 2006-09-14
EP0760671B1 (de) 2005-08-17
CA2191202A1 (en) 1995-11-30

Similar Documents

Publication Publication Date Title
BR9306820A (pt) Conjugado de um antígeno fracamente imunogênico e um veículo peptideo sintetico vacina processos para melhorar a imunogenicidade de uma molecula de antigeno fracamente imunogenico e para imunizar um hospedeiro mamífero
ATE302016T1 (de) Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind
FI943591A7 (fi) Synteettinen hemofilus-influenssa yhdistelmärokote
DE69111801D1 (de) Vakzin gegen hepatitis b.
DE69839587D1 (de) Enterokokkus antigene und vakzine
DK174416B1 (da) Oligopeptider, immunogene konjugater heraf med et antigen samt vacciner indeholdende disse konjugater
WO1995029193A3 (en) Melanoma antigens
CA2290485A1 (en) Method for the production of non-immunogenic proteins
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
NO20011381L (no) Preparater av streptokokk C<beta>-protein
AU3234295A (en) Influenza virus subunit conjugates
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
ATE221786T1 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
AU3193897A (en) Vaccine comprising antigens bound to carriers through labile bonds
GB2314560A (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use
ES1027961U (es) Soporte publicitario para carritos.
ES2065254A1 (es) Peptidos y vacunas sinteticas contra parvovirus canino y otros virus relacionados.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties